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OBJECTIVE—-Cell regeneration is a fundamental but elusive
goal for type 1 diabetes research. Our objective is to review
newer human and animal studies of -cell destruction and
regeneration and consider the implications for treatment of type
1 diabetes.
RESEARCH DESIGN AND METHODS—Recent human and
animal studies of -cell destruction and regeneration in type 1
diabetes are reviewed.
RESULTS—The loss of -cells that characterizes type 1 diabetes
reﬂects the net effects of destruction and regeneration. These
processes have been examined in the nonobese diabetic (NOD)
mouse; uncertainty remains about -cell dynamics in humans.
Islet inﬂammation stimulates -cell replication that produces
new insulin-positive cells. The regenerative process may tide the
loss of overall -cell function, but it also may enhance the
autoimmune attack on -cells by providing new epitopes. The
highest rates of -cell replication are at the time of diagnosis of
diabetes in NOD mice, and if autoimmunity and islet inﬂamma-
tion are arrested, new -cells are formed. However, the majority
of -cells after treatment with immune modulators such as
anti-CD3 monoclonal antibody, and most likely during the “hon-
eymoon” in human disease, are recovered -cells that had been
degranulated but present at the time of diagnosis of diabetes.
CONCLUSIONS—Residual -cells play a signiﬁcant role for the
design of therapeutic trials: they not only may respond to
combination therapies that include stimulants of metabolic func-
tion but are also the potential source of new -cells. Diabetes
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tudies largely done in nonobese diabetic (NOD)
mice have described a linear loss of -cell mass
from the time of initiation of insulitis through
presentation with hyperglycemia and afterward
until there is complete loss of -cells (1,2). Results from
the Diabetes Prevention Trial-1 (DPT-1) have described
changes in insulin secretion from pre-diabetes to presen-
tation with hyperglycemia, and other studies have de-
picted the progressive loss of insulin secretion after
diagnosis (3–5). Whereas the data from animal studies and
clinical investigations are largely consistent, other studies
indicate that a simple linear loss of -cell function may be
an oversimpliﬁcation of a process that involves an undu-
lating downhill course. Variation in the rate of progression
of -cell loss may be due to waxing and waning of the
inﬂammatory response because of exposure of new anti-
gens; intercurrent insults to -cells involving infectious
agents, metabolic demands, or other factors; and a contin-
uous attempt at -cell regeneration that tides the progres-
sion. Inﬂammation itself appears to stimulate -cell
regeneration, but at the same time may expose new
antigenic epitopes that become the drivers of a broadening
autoimmune response (6). Ultimately, the failure to con-
tain and counter this enlarging process results in presen-
tation with clinical disease. Understanding the way in
which the process develops and progresses has implica-
tions for treatment and reversal of the disease.
-cell turnover is increased during progression of
diabetes. In NOD mice, -cell proliferation increases with
islet inﬂammation during progression of diabetes. By 4
weeks of age, the proportion of Ki67
insulin-positive cells
in the islets of Langerhans in NOD mice is signiﬁcantly
increased compared with control NOD/scid mice that do
not have insulitis (7). -Cell proliferation continues to
increase, with insulitis, during the development of disease;
by 12 weeks of age, 3.03  0.94% of insulin-positive cells
are Ki67
. The highest levels of Ki67
insulin-positive cells
are found at the time that the mice develop hyperglycemia.
The increased rate of -cell proliferation is found even
before a signiﬁcant decline in -cell mass or an increase in
glucose levels suggesting that metabolic demands per se
are not responsible for the -cell proliferation. Similar
ﬁndings of heightened proliferation of -cells were re-
ported by Sreenan et al. (1) using bromodeoxyuridine
(BrdU) labeling. These investigators also found an inverse
change in -cell mass and proliferation rates.
The -cell proliferation is linked to islet inﬂammation
(7). It increases in the recipients of diabetogenic spleen
cells that are transferred to NOD/scid recipients. By 4
weeks after transfer of cells, the rates of -cell replication
increases more than 10-fold compared with NOD/scid
mice (from 0.22  0.05% to 3.14  1.07%, P  0.007) (7).
Measures that modulate islet inﬂammation decrease -cell
proliferation. After treatment with anti-CD3 monoclonal
antibody (mAb), -cell proliferation fell from 3.09  0.8%
(at diagnosis) to 1.57  0.28% 3 weeks after treatment (P 
0.05). Moreover, when diabetogenic spleen cells were
transferred into NOD/scid recipients together with
CD4
CD25
 regulatory T-cells, the rate of diabetes de-
creased from 79 to 17% (P  0.01), but -cell proliferation
also decreased from 2.95  0.27 to 1.98  0.26%.
The increased rates of -cell proliferation that are found
in mice with insulitis result in an increase in the mass of
“new” -cells if autoimmunity is arrested. To demonstrate
this directly, we treated hyperglycemic NOD mice with
anti-CD3 mAb to reverse hyperglycemia, studied the
changes in -cell area after treatment, and enumerated the
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added BrdU to the drinking water of the mice after
treatment with anti-CD3 mAb and enumerated the “new”
-cells in the islets after euglycemia was established. In
the islets of these mice, 10.9  1.38% of the -cells were
BrdU
 3 weeks after mAb treatment compared with
4.22  0.49% of the -cells in untreated NOD/scid mice
that were given BrdU over the same period of time (P 
0.001) (7).
These ﬁndings are consistent with the recent report by
Nir et al. (8) that there may be spontaneous recovery of
-cell mass and function in the absence of autoimmunity.
In these studies, the investigators acutely eliminated 70–
80% of -cells by the transgenic expression of diphtheria
toxin. When the transgene expression was quenched,
hyperglycemia resolved over a 4-week period and -cell
mass increased. Dor, Melton, and colleagues (9) have
previously observed that -cell mass expansion primarily
occurs via insulin-positive precursors. Indeed, diphtheria-
mediated -cell mass reduction primarily occurs by expan-
sion of insulin-positive progenitors (8). New data indicate
specialized progenitors do not contribute to -cell mass
growth or regeneration (10,11). Taken together, these
studies suggest that -cell mass in young rodents is highly
dynamic and that non–autoimmune-stimulated -cell re-
generation primarily occurs via simple -cell replication.
Despite the consistent evidence for -cell regeneration
in rodents, it is not clear whether similar -cell dynamics
occur in humans. Butler et al. (12) did not ﬁnd evidence for
increased -cell replication in patients with recent-onset
diabetes who died of ketoacidosis compared with age-
matched subjects. In’t Veld et al. (13) did identify
Ki67
insulin-positive cells in islets with insulitis in anti-
islet autoantibody–positive organ donors, but the percent-
age of islets in the pancreas with insulitis was small (3 and
9%). However, there are differences between the material
sampled in these two reports and the pancreases of NOD
mice that develop diabetes. The timing of the analysis is
different in patients with diabetes compared with pre-
diabetic NOD mice, and in the case of the organ donors, it
is not clear whether the pathologic process that was
studied would in fact lead to diabetes. Nonetheless, these
observational studies identify a number of important dif-
ferences between human disease and the NOD model.
First, the proliferative responses of human islets may be
different from those seen in rodents. Second, the inﬂam-
matory response in islets of patients with diabetes is
clearly different from that seen in NOD mice in which
inﬂammatory inﬁltrates that permeate and often obliterate
islets are routinely seen (14). The insulitis that occurs in
patients is reduced, involving 0–33% of islets and in only
52% of islets, and the modest cellular inﬁltrate is predom-
inated by CD8
 T-cells (15,16).
The dynamic process of new -cell formation and
-cell destruction creates an environment for ex-
pression and presentation of new antigenic targets.
The mechanisms involved in the destruction of -cells
have been the subject of intensive research and include
direct lysis of -cells by CD8
 T-cells or other lytic cells,
the damaging effects of cytokines that are produced by
effector CD4
 T-cells that recognize their antigenic targets
on non–-cells, or even by non–T-cells that release innate
inﬂammatory mediators, such as interleukin (IL)-1,
which can damage -cells and break tolerance through
activation of adaptive responses (17–25). The turnover of
-cells may fuel this process through the expression of
new antigens or possibly by post-translational modiﬁca-
tion of proteins, which has been described in other disease
settings (6,26–28). Some experimental evidence suggests
that -cell death throughout the life of NOD mice during
development primes autoreactive T-cells. The detection of
dead -cells in pancreatic lymph nodes by day 20 of age
and the ability of isolated dendritic cells from these lymph
nodes to stimulate the TCR transgenic diabetogenic T-cell,
BDC2.5, provides an indication for the role of -cell death
and contraction during development in the priming of
autoreactive T-cells (29). -Cell injury and death may
underlie the spreading of speciﬁcities of pathogenic auto-
immune cells during progression of disease by exposing
new epitopes (30). Epitope spreading allows for the acti-
vation of new T- and B-cell clones in response to novel
antigens that are expressed in the target organ. Isolated
T-cells from NOD mice showed a wider ability to respond
to novel intramolecular determinants of GAD65, which
increased with age (31). In fact, tolerized NOD mice
showed reduced recognition of novel epitope by autore-
active T-cells and protection from disease. Not only in-
tramolecular but also intermolecular epitope spreading is
observed in the NOD mouse (32).
At least one protein, reg, is involved in -cell prolifera-
tion and can serve as an autoantigen (33,34). In the NOD
mouse, array studies have shown reg gene expression
during progression of disease as one of the products to
which cellular immune responses ultimately develop (26).
The recognition of new antigens may be the consequence
or the cause of progression. Ott et al. (35) have examined
the reactivity of T-cells from type 1 diabetic patients,
people at high risk of developing diabetes, and healthy
control subjects who respond to GAD65 and proinsulin in
vitro. The authors demonstrated increased T-cell reactivity
to GAD65 antigens and to proinsulin in both type 1
diabetic patients and high-risk individuals. T-cell reactivity
to whole protein and the variable memory response in
different type 1 diabetic patients led the authors to con-
clude that cryptic epitopes are recognized in type 1
diabetes. They found that epitope spreading occurs in
these individuals, whereas these cryptic epitopes do not
activate T-cells from individuals who do not progress to
disease.
The acquisition of antigenicity during progression of
diabetes is more accurately described as instructive rather
than stochastic. There is an orderly unfolding of antigenic
responses over time: there is a hierarchy of antigens.
Recent studies by Nakayama et al. and Krishnamurthy et
al. support the notion that insulin is a “primary” antigen in
NOD diabetes, whereas the islet-speciﬁc G6Pase catalytic
subunit-related protein (IGRP), clearly an antigen recog-
nized by diabetogenic T-cells later in the course of the
disease, appears to be secondary. Insulin 1 and insulin 2
gene knockout mice with a mutated proinsulin transgene
(in which residue 16 on the B-chain was changed to
alanine) in NOD mice did not develop insulin autoantibod-
ies, insulitis, or diabetes (36). NOD mice tolerized to
proinsulin did not develop cytotoxic IGRP-reactive T-cells
or diabetes, whereas mice tolerized to IGRP did not
develop IGRP reactive T-cells but did develop diabetes
(22). These results provide direct evidence that the re-
sponse against IGRP is downstream of the response to
proinsulin in this model. Human data are also consistent
with this notion: autoantibody responses to insulin are
highest in younger individuals and the risk of disease
increases with the number of antigens that are recognized
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targets is cross-sectional rather than prospective, but the
available evidence supports a sequential rather than simul-
taneous appearance of autoantigen reactivity (38).
Presentation with hyperglycemia reﬂects a transient
shift in the dynamic process that may be precipitated
by acute islet inﬂammation, increased insulin resis-
tance, or other factors. As -cell mass declines, a critical
level is reached at which small disturbances in either
insulin requirements or insulin production can have a large
effect on the clinical picture. Acute viral infections are one
example. Coxsackie B4 virus has been isolated from the
blood of patients with new-onset diabetes, and certain of
these isolates have been shown to cause diabetes in mice
(40). Histopathologic studies have shown expression of
IFN- in the islets of individuals who have died at the time
of presentation of type 1 diabetes (A. Poulous, personal
communication). A recent study found evidence for infec-
tion with Coxsackie B4 enterovirus in the pancreata of
three of six patients with type 1 diabetes whose pancreas
was examined up to 9 months after diagnosis (a pancreas
graft was studied from one patient) (41). Interestingly, in
two of the patients, the number of -cells was similar to
that from three age-matched nondiabetic control subjects,
whereas in three patients, the islets with enterovirus
showed reduced insulin secretion in response to secreta-
gogues and the virus from the islets could infect islets
from nondiabetic donors and cause viral inclusions and
pyknosis. There was NK cell (CD94
) and to a lesser
extent T-cell inﬁltration, occasional B-cell and CD68
 cell
inﬁltration, and IFN- expression in three of the patients,
suggesting ongoing or previous islet viral infection.
In addition to reduced insulin production, insulin resis-
tance has been suggested as an accelerator of diabetes at
presentation. Insulin resistance has been thought to con-
tribute to the frequent presentation of type 1 diabetes
during adolescence when insulin sensitivity declines. In-
nate immune responses may account both for impaired
insulin sensitivity as well as a decline in -cell function
(42). Koulmanda et al. (43) found that “triple therapy” with
rapamycin, IL-2 Ig, and IL-15 Ig, which reversed hypergly-
cemia in NOD mice, dampened the expression of inﬂam-
matory genes including IL-1, tumor necrosis factor-, and
granzyme in diabetic mice. Interestingly, these investiga-
tors found that the triple therapy restored insulin signaling
in peripheral tissues suggesting that inﬂammatory media-
tors may affect responses as well as production of insulin.
This is consistent with clinical ﬁndings of insulin resis-
tance at the time of presentation of diabetes and the
widely recognized role of inﬂammatory products such as
tumor necrosis factor- in mediating it (44,45). In addition,
prospective human data from the Diabetes Prevention
Trial have shown that factors other than a precipitous
decline in insulin secretion account for clinical presenta-
tion. The comparison between the C-peptide responses to
either a mixed meal or oral glucose before and after
diagnosis showed only a modest difference, where the
major effect is on the peak C-peptide response to the
metabolic challenge. Basal insulin secretion is relatively
well preserved at the time of diagnosis (3,5,46). In our
studies of -cell function before and after diagnosis, the
C-peptide response to a mixed-meal test after diagnosis
was 87  7% (n  31) of the prediagnosis response. It was
on a third test, in a subset of the original subjects, that was
done 6 months or more later, that a more dramatic
decrease to 53  13% (n  10) of the response before
diagnosis was seen. In an analysis of the C-peptide re-
sponse to an oral glucose tolerance test, the total C-
peptide area under the curve was reduced by 18% from 6
months before to after diagnosis. These studies suggest
that in addition to the decline in C-peptide responses,
additional factors are involved in the metabolic decompen-
sation at presentation.
-Cell area degranulation and regranulation? In NOD
mice, there is a precipitous drop in the -cell area at
presentation with hyperglycemia (2). The effects of the
acute precipitants of disease may not be permanent and
may be partially reversible. Indeed, the rapid recovery of
-cell function after the diagnosis during the “honeymoon”
period suggests a reversible component to the metabolic
dysfunction at diagnosis. Our studies of -cell mass in
NOD mice at diagnosis of type 1 diabetes are consistent
with this notion. As noted above, there was a signiﬁcant
increase in -cell area after treatment with anti-CD3 mAb,
but only 11% of the -cells were new (i.e., BrdU
 and
insulin-positive). Therefore, 90% of the -cells had been
present in the islets at the time of presentation with
hyperglycemia. The difference between the total area after
correction of hyperglycemia (0.367  0.065 mm
2) and the
-cell area found at diagnosis (0.086  0.04 mm
2) plus the
11% of the -cells that had been newly formed (0.037 mm
2)
does not account for the entire -cell mass. This suggests
that there had been -cells in the islets at the time of
diagnosis that could not be identiﬁed by conventional
staining with insulin and accounted for over half of the
-cells that were found after correction of hyperglycemia.
When we stained islets from mice with new-onset diabetes
with antibodies to GLUT2, we identiﬁed GLUT2
 insulin
cells in the islets at diagnosis, but all of the GLUT2
 cells
in the islets after treatment with anti-CD3 mAb were
insulin-positive. The GLUT2
 insulin cells that were found
in the islets at diagnosis may represent a functionally
“exhausted” or degranulated pool of cells that have not
been destroyed and may recover. Thus, the precipitation
of disease onset may involve a rapidly accelerating cycle in
which an initial loss of -cell function, due to inﬂamma-
tory mediators, coupled with a reduced -cell mass after
autoimmune destruction, results in modest hyperglycemia,
which is met by increased demands on the residual -cells
to produce insulin (Fig. 1). If the expansion of -cell mass
or improvement in function does not keep pace with the
demands, additional -cells may become functionally ex-
hausted and degranulated leading to worsening degrees of
hyperglycemia (47,48). The immediate recovery after the
initial treatment with immune modulators and/or even
insulin involves the net effect of -cell replication during
islet inﬂammation, but even more signiﬁcantly, the recov-
ery of -cell function that was reduced at the time of
diagnosis. It should be noted, however, that although
insulin treatment and correction of the decompensated
metabolic conditions results in temporary improvement in
insulin responses in humans, a similar “honeymoon” does
not occur in NOD mice treated with insulin. The differ-
ences between mice and humans could reﬂect differences
in the relative pace of the autoimmune process or the
signiﬁcant impact of the precipitants of human disease. It
may also reﬂect our relatively poor ability to control the
glucose level in NOD mice with new-onset diabetes. This
resulting condition, however, is precarious because mod-
est increases in insulin requirements, inﬂammatory insults
to the islets, or progression of the anti-islet adaptive
response may result in recurrence of the cycle.
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cepts regarding the dynamics of -cell mass in type 1
diabetes have implications for the design of clinical inter-
ventions that are targeted to arrest the adaptive autoim-
mune response. First, the total amount of residual -cell
mass is an important variable in the outcome of immune
intervention. Metabolic interventions will only be effective
if there is sufﬁcient -cell mass with which they can work.
Furthermore, some studies indicate that new -cells are
derived by replication of existing cells and therefore
growth of the total -cell mass will be more substantial
with greater starting material (9–11). The clinical data
have supported the importance of residual -cell function
in promoting responses to interventions. In the studies of
anti-CD3 mAb by Keymeulen et al. (49), the greatest
responses to the immune intervention were in individuals
with the highest C-peptide levels at the time of diagnosis.
To improve the recovery of diabetes in NOD mice after
anti-CD3 mAb, we tested the addition of the GLP-1 recep-
tor agonist, exendin-4, to treatment with anti-CD3 mAb
(50). Previous studies had indicated that exendin-4 in-
creased replication of -cells in rodents and had glucose-
lowering effects in mice and humans (51–54). We found
that exendin-4 enhanced the reversal of diabetes in mice in
which the glucose level was 350 mg/dl at the time of
diagnosis. These mice would be expected to have a
residual -cell mass that is greater than those with higher
glucose levels at diagnosis in which the exendin-4 and
anti-CD3 mAb were less effective. The total -cell area and
rate of -cell proliferation was similar in islets from mice
that did or did not receive exendin-4 with anti-CD3 mAb.
The exendin-4 treatment did not have an effect on the
immune response or the antigenicity of the islets. How-
ever, the glucose tolerance of the exendin-4–treated mice
and the insulin content of their pancreases were improved
compared with those treated with just the anti-CD3 mAb.
Thus, it may be possible to enhance the efﬁcacy of single
immunologic agents by combining them with agents that
have other mechanisms such as enhancing -cell function.
With this combination, the efﬁcacy of the combination will
depend on the residual -cell mass that can be affected by
the drug.
Finally, in our studies, immune therapy diminished the
replicative response of -cells that are found during devel-
opment of diabetes. More than 6 weeks after treatment of
NOD mice with anti-CD3 mAb, -cell replication fell to
levels that were less than in younger mice but were still
higher than in control (NOD/scid) mice (1.11  0.15 vs.
0.37  0.07%, P  0.001) (7), possibly reﬂecting some
degree of ongoing inﬂammation or residual -cell deﬁcit.
The “boost” of -cell replication that occurs during inﬂam-
mation may therefore decline, but the recent studies by
Nir et al. (8) imply that there may be spontaneous recovery
of -cell mass if inﬂammation and autoimmunity are
prevented.
In summary, clinical and preclinical studies suggest that
there is a progressive loss of -cell mass and function from
the initiation of insulitis through presentation with hyper-
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FIG. 1. Changes in -cells during progression of type 1 diabetes and the selection of interventions: the initial event that primes the adaptive
immune response is not known but is postulated to involve -cell death. Antigen-speciﬁc immune interventions (red arrow) have the greatest
chance of efﬁcacy in this early stage. With progression of the response, there are increased rates of -cell proliferation but also a loss of -cells
and expansion of the immune response. A greater proportion of replicating -cells is seen in the islet as insulitis progresses, and some -cells are
unable to keep up with the metabolic demands. Most likely, a broader approach to immune intervention is needed at this point, since the
autoreactive repertoire is broader than at the earlier stages. Left untreated, there is continued loss of -cells. However, interventions such as
immune modulators can prevent the ongoing adaptive immune response against -cells and, with metabolic treatment, recovery of degranulated
-cells can occur.
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and in mice, reﬂects the opposing factors of -cell destruc-
tion by an expanding adaptive immune response, -cell
replication, and the effects of acute insults with infectious
agents and other inﬂammatory mediators. The accelerated
rates of -cell turnover during progression may be an
incendiary to the process by providing and presenting new
antigenic targets. This model has largely been developed
in mice; human studies have yet to conﬁrm the -cell
replicative process or even the extent of insulitis that is
found in the NOD mouse. At the time of diagnosis, a
critical threshold of -cell function has been crossed, but
there is potentially recoverable -cell mass that can re-
store -cell function to a prediagnosis level. However,
even with recovery, -cell mass is signiﬁcantly reduced.
Therefore, increases in insulin demand or further progres-
sion of the immune process results in signiﬁcant clinical
consequences and further loss of -cells. The time at
which the progression of disease is identiﬁed and treated
with immune modiﬁers is of practical importance, since
the residual cells may represent the source of new -cells
and combination agents are more likely to be effective if
there are -cells that can respond.
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